Margetuximab with retifanlimab as first-line therapy in HER2D/PD-L1D unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A

Catenacci, DVT; Kang, YK; Yoon, HH; Shim, BY; Kim, ST; Oh, DY; Spira, AI; Ulahannan, SV; Avery, EJ; Boland, PM; Chao, J; Chung, HC; Gardner, F; Klempner, SJ; Lee, KW; Oh, SC; Peguero, J; Sonbol, MB; Shen, L; Moehler, M; Sun, J; Li, D; Rosales, MK; Park, H

Catenacci, DVT (通讯作者)，900 East 57th St,KCBD Bldg,Off 7128, Chicago, IL 60637 USA.

ESMO OPEN, 2022; 7 (5):

Abstract

Background: Human epidermal growth factor receptor 2 (HER2)- positive metastatic gastric and gastroesophageal adenocarcinoma (GEA) is globally treated......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索